Indeed, this approach addresses the present challenges facing cancer treatment, influencing the tumour microenvironment by permitting the recruitment of active immune cells, lowering immune checkpoint activity, and reducing PD‐L1 expression at the endothelial cell level to allow the entry of immune cells into the tumour. The gene discussed is CD274; the disease is neoplasm.